Oligometastases/Oligo-Recurrence of Lung Cancer

[...]for a long time, cancer patients with metastasis or recurrence have been classified as one group and treated using only systemic therapy. Favorable Intermediate Unfavorable Relatively favorable Relatively unfavorable Oligorecurrence Site no. 1-2 NSCLC (brain and adrenal gland) Colon and rectum cancer (lung and liver) Renal cell cancer oligo-recurrence site no. 1-2 breast cancer (bone, lung, and liver) SCLC (brain) site no. 3–5 NSCLC (brain and adrenal gland) colon and rectum cancer (lung and liver) renal cell cancer oligo-recurrence site no. 3–5 breast cancer (bone, lung, and liver) SCLC (brain) Oligometastases and oligo-recurrence pancreatic cancer (any site) melanoma (any site) sarcoma (any site) sync-oligometastases site no. 1-2 NSCLC (brain and adrenal gland) colon and rectum cancer (lung and liver) renal cell cancer sync-oligometastases site no. 3–5 NSCLC (brain and adrenal gland) colon and rectum cancer (lung and liver) breast cancer (bone, lung, and liver) polymetastases This new classification, the Niibe-Onishi-Chang classification, should be revised in the future due to the rapid improvements being achieved in local and systemic therapies for cancer. [4] J. L. Lopez Guerra, D. Gomez, Y. Zhuang, D. S. Hong, J. V. Heymach, S. G. Swisher, S. H. Lin, R. Komaki, J. D. Cox, Z. Liao, "Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis," International Journal of Radiation Oncology, Biology, Physics, vol. 84 no. 1, pp. e61-e67, DOI: 10.1016/j.ijrobp.2012.02.054, 2012. [9] R. Holy, M. Piroth, M. Pinkawa, M. J. Eble, "Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer," Strahlentherapie und Onkologie, vol. 187 no. 4, pp. 245-251, DOI: 10.1007/s00066-011-2192-z, 2011.